Exciting New Awards Granted!
Justin Silver The National Fragile X Foundation is pleased to announce the 2013 recipients of The Justin Silver Award for Innovative Services. Established by the Silver Family in honor of their son Justin, these [...]
NIH Funds Expansion of Research on iPad-Assisted Language Development
Photo courtesy of Autism Speaks The National Institutes of Health has awarded a major grant to conduct a clinical trial on iPad Assisted Language Development. An Autism Speaks funded study reported encouraging findings on [...]
UNC Child Neurologist Finds Potential Route to Better Treatments for Fragile X, Autism
Contact: Mark Derewicz mark.derewicz@unch.unc.edu (919) 923-0959 University of North Carolina Health Care CHAPEL HILL, N.C. – When you experience something, neurons in the brain send chemical signals called neurotransmitters across synapses to receptors on other [...]
UMass Medical School: Genetic Mutation Found to Restore Translational Balance in Mice with FXS Mutation
Joel Richter, PhD, professor of molecular medicine(Photo Courtesy of UMassMedNow) Scientists at UMass Medical School have shown that knocking out a gene important for messenger RNA (mRNA) translation in neurons restores memory deficits [...]
FDA Approves New Drug Trial for Fragile X Syndrome
Neuren Pharmaceuticals (NEU) has received approval from the US Food and Drug Administration to conduct a Phase 2 clinical trial of a drug to treat patients with Fragile X syndrome (FXS), the company recently announced. [...]
Study Shows Professionals Still Have Much to Learn About Fragile X
A recent study by Brenda Finucane of the Geisinger Health System and her colleagues reveals that many educators and therapists still know little about Fragile X syndrome (FXS). Brenda Finucane is an NFXF Scientific & [...]
All Genes Are Not Created Equal
The gene and protein responsible for causing Fragile X syndrome emerges as a leading candidate in the search for the cause of autism and maybe even schizophrenia.
Fragile X Drug Developer SAGE Therapeutics Names New Chief Executive
New SAGE Therapeutics chief executive Jeffrey Jonas will oversee the company’s drug development program for Fragile X syndrome, which last month received a grant worth up to $10 million from the National Institutes of Health.
NIH Launches Neurological Drug Development Projects Including Fragile X Syndrome
The National Institutes of Health (NIH) has launched three projects that will focus on development of therapeutics, including one project for Fragile X syndrome. "We are excited about the opportunity to apply cutting-edge science to [...]
Open Letter to the FX Community about Seaside Arbaclofen (STX209)
To our Fragile X family: Many of you by now have heard the news that Seaside Therapeutics has decided to end their extension of the trial medication known as Arbaclofen (STX209). The NFXF Board of [...]
Seaside Therapeutics Announces End of Arbaclofen (STX209) Extension Study
Late yesterday afternoon the NFXF, along with all of the study locations, was contacted by Seaside Therapeutics and informed that the “Study 209FX303 [An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of [...]
New Research Leads to Better Understanding of FXTAS
The NFXF was excited to read this announcement from the University of Michigan Health System. There are a number of dedicated scientists and clinicians working on FXTAS, however new treatments have been slower in coming than for Fragile X syndrome.
Public Policy at Work: Abbeduto Given $3M NICHD Grant to Study Fragile X
The UC Davis MIND Institute reported on its website that a $3 million grant will allow their research team to investigate the effectiveness of testing procedures to examine the spoken language development of people with Fragile [...]
Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice, Promising Autism Treatment
“These findings suggest a possible novel therapeutic target for the treatment of Fragile X Syndrome (FXS) — the most common inherited form of autism and intellectual disability,” said Eric Klann, a professor of neural science at New York University.
Cholesterol Drug May Treat Fragile X Syndrome
The investigator cited in this article, Dr. Emily Osterweill, was previously funded by the National Fragile X Foundation for her work on mGluR5. -- Cholesterol drug may treat Fragile X syndrome -- A cholesterol-lowering drug called lovastatin prevents seizures in mice that model Fragile X syndrome, according to a poster presented Sunday at the 2012 Society for Neuroscience annual meeting in New Orleans.